CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• A Miniaturized, Semi-Automated RNA-seq Workflow

  A streamlined RNA‑seq workflow enables high‑throughput gene expression profiling directly from cell lysates, reducing cost and complexity. See how this approach accelerates lead selection.

• Comparing Serum-free To Serum-Supplemented Media

  Reducing serum in vaccine manufacturing is a key consideration for lowering costs and improving supply security. We compare performance in serum-free versus serum-supplemented media.

• Protect Your Columns And Your Peaks

  Learn how thoughtful filter selection can protect LC systems, improve protein recovery, and support reliable chromatographic results with key performance data and solvent compatibility insights.

• Unlock The Power Of Clinical Data Science

  Discover a unified, AI‑driven approach that helps clinical teams manage growing data complexity, accelerate insight generation, and improve trial oversight to enable faster decisions.

• AAV-Based Gene Editing For Huntington's Disease

  LETI-101 uses AAV5 to deliver a compact CRISPR system for allele-selective editing of mutant HTT, showing promise as a one-time treatment for Huntington’s disease with strong preclinical safety and efficacy.

• An Innovative, Modular Approach To Flexible Supply Chain Management

  Learn how modular strategies, global coordination, and data-driven decisions help maintain continuity, compliance, and speed amid constant uncertainty.

• Decoding AAV: Navigating Critical Quality Attributes And Their Analytics

  For groundbreaking genetic treatments, stringent quality control is non-negotiable. This exploration delves into defining essential attributes and the analytical tools that safeguard their consistent production.

• Chimeric Antigen Receptor Plasmid Production

  Parallel single-use bioreactor setups enable faster optimization, improved reproducibility, and smoother transition from development to production—supporting more efficient and consistent cell therapy workflows.

• Evaluation Of TFF Operating Control Strategies And Scalability

  Gain insight into a comparison of TMP and permeate control strategies for viral vector TFF, highlighting impacts on flux, processing time, impurity removal, and scale-up predictability across development.

• T Cells In Immunotherapies: The Key Progress Underway

  CAR-T therapies now make up 73% of active pipeline programs, yet solid tumors remain largely out of reach. Where is T cell immunotherapy headed next, and what does it mean for your pipeline strategy?